ANI Pharmaceuticals, Inc. is a bio-pharmaceutical company, which engages in the development, manufacture, and marketing of branded and generic prescription pharmaceuticals. The company is headquartered in Baudette, Minnesota and currently employs 897 full-time employees. The company went IPO on 2000-05-04. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
How did ANIP's recent EPS compare to expectations?
The most recent EPS for ANI Pharmaceuticals Inc is $2.33, beating expectations of $2.03.
How did ANI Pharmaceuticals Inc ANIP's revenue perform in the last quarter?
ANI Pharmaceuticals Inc revenue for the last quarter is $2.33
What is the revenue estimate for ANI Pharmaceuticals Inc?
According to 8 of Wall street analyst, the revenue estimate of ANI Pharmaceuticals Inc range from $281.93M to $250.59M
What's the earning quality score for ANI Pharmaceuticals Inc?
ANI Pharmaceuticals Inc has a earning quality score of B+/55.249832. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does ANI Pharmaceuticals Inc report earnings?
ANI Pharmaceuticals Inc next earnings report is expected in 2026-05-28
What are ANI Pharmaceuticals Inc's expected earnings?
ANI Pharmaceuticals Inc expected earnings is $236.16M, according to wall-street analysts.
Did ANI Pharmaceuticals Inc beat earnings expectations?
ANI Pharmaceuticals Inc recent earnings of $247.06M beat expectations.